Novartis AG (NYSE:NVS) has decided to terminate the Collaboration and License Agreement with Pliant Therapeutics, Inc.(NASDAQ:PLRX), announced in 2019. Novartis told…
Novartis (NYSE:NVS) reported quarterly earnings of $1.52 per share which beat the analyst consensus estimate of $1.44 by 5.56 percent. This is a 8.57 percent increase over earnings of $1.40 per share from the same period
With a full week of earnings behind us, it’s time to take stock of the fourth-quarter reporting season so far. Overall, the news flow has been mixed, although tech earnings have grossly disappointed.
Psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) has successfully completed two drug discovery projects with leading scientists at the Hebrew University of Jerusalem.